

#3

Deborah A. Dugan, Esq.  
deborah.dugan@genzyme.com  
Metrowest Place, 15 Pleasant Street Connector  
Framingham, Massachusetts 01701-9322  
Telephone: (508) 270-2598  
Facsimile: (508) 872-5415

**GENZYME  
CORPORATION**

# Fax

To: Ms. Stokes

From: Deborah A. Dugan

Initial Patent Exam Div., USPTO

Genzyme Corporation

Fax: (703) 308-7751

Pages: 7 including cover page

Phone: (703) 308-1202

Date: March 19, 2002

Re: Our Reference: GA0118USC; Your Reference: 10/041,977


**Urgent For Review** **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

• **Comments:** Dear Ms. Stokes: Further to our telephone conversation today regarding the Notice to File Missing Parts (mailed 03/07/02) for USSN 10/041,977; the Notice indicating that "the oath or declaration is unsigned". Pursuant to your request, attached hereto are copies of the following documents:

- Postcard acknowledging receipt by the USPTO of a Declaration/POA consisting of three (3) pages;
- Notice mailed 03/07/02; and
- Fully executed Declaration and Power of Attorney filed with the subject application on November 20, 2001 (and received by the USPTO on January 9, 2002).

Thank you for: (i) correcting the file history to indicate that the application was filed with a fully executed Declaration and Power of Attorney; and for (ii) reissuing a Notice to File Missing Parts for the sequence listing.

Sincerely, Deborah A. Dugan, Reg. No. 37,315



NOTICE OF CONFIDENTIALITY

This transmission is intended only for the addressee(s) listed above and may contain information that is confidential and privileged. If you are not the intended recipient or an agent responsible for delivering to the intended recipient, you are hereby notified you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If you have received this transmission in error, please telephone us immediately and return the original message to us by mail. Thank you.

03/19/02





## UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/041,977	01/09/2002	Charles A. Nicolette	GA0118USC

24536  
GENZYME CORPORATION  
LEGAL DEPARTMENT  
15 PLEASANT ST CONNECTOR  
FRAMINGHAM, MA 01701-9322

CONFIRMATION NO. 7476

## FORMALITIES LETTER



\*OC000000007600675\*

Date Mailed: 03/07/2002

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at

patin21help@uspto.gov or patin3help@uspto.g v

---

*A copy of this notice MUST be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY